{"id":"W4389657620","doi":"10.1016/s1474-4422(23)00403-9","title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Impact; McMaster University; Population Health Research Institute","funders":"European Stroke Organisation; Janssen Research and Development; HLS Therapeutics; Ipsen; Janssen Pharmaceuticals; Göteborgs Universitet; Deutsches Zentrum für Neurodegenerative Erkrankungen; Daiichi Sankyo Europe; Sanofi; Deutsches Zentrum für Herz-Kreislaufforschung; Sahlgrenska Universitetssjukhuset; American Stroke Association; Alexion Pharmaceuticals; Amgen; National Heart, Lung, and Blood Institute; Pfizer; Inventiva Pharma; Bristol-Myers Squibb; AstraZeneca; Novo Nordisk; American Heart Association","keywords":"Medicine; Placebo; Stroke (engine); Aspirin; Population; Clopidogrel; Risk factor; Clinical endpoint; Internal medicine; Randomized controlled trial; Anesthesia; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002234204,0.002531329,0.0043067,0.0004754734,0.0005380587,0.001587702,0.001120723,0.002583961,0.007061792],"category_scores_gemma":[0.001972616,0.0008744076,0.002536837,0.0004176371,0.001609778,0.001579396,0.0004726464,0.004414313,0.001265666],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006991189,"about_ca_system_score_gemma":0.0009460805,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006369053,"about_ca_topic_score_gemma":0.001251649,"domain_scores_codex":[0.9993731,0.0002984703,0.00004039472,0.0001178228,0.00005179934,0.0001183349],"domain_scores_gemma":[0.999186,0.000283237,0.0001590319,0.00008377892,0.00006006306,0.0002279612],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9797044,0.003947094,0.0002932543,0.0007556138,0.001306337,0.00003212692,0.00003613278,0.0001811323,0.001758289,0.0001354024,0.0007110476,0.01113916],"study_design_scores_gemma":[0.9666715,0.03144783,0.0006253155,0.00002636741,0.0003940261,0.0000234325,0.00001174874,0.0001864161,0.0002200793,0.0001457364,0.0002350287,0.00001254466],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9792421,0.01050559,0.001351852,0.001174911,0.0008687389,0.002468673,0.001190737,0.000277484,0.002919851],"genre_scores_gemma":[0.9832588,0.005249245,0.001911046,0.001962192,0.0006667196,0.002398026,0.00144601,0.00004217142,0.003065817],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007061792,"threshold_uncertainty_score":0.023624,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06879306530208357,"score_gpt":0.35347818787607,"score_spread":0.2846851225739864,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}